GlassScriptPhysician profile
Alexis B Shaefer
NPI 1942590872
$279,100.41
in general payments reported to CMS, 2019-2025
65 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,842 · 2020: $46K · 2021: $63K · 2022: $67K · 2023: $20K · 2024: $48K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $15K · Food and Beverage: $14K · Consulting Fee: $6,453 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,107.50 |
| Travel and Lodging | $14,522.96 |
| Food and Beverage | $14,339.46 |
| Consulting Fee | $6,452.50 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140,468.90 | 2020-2025 | Ubrelvy, Qulipta, Botox |
| Takeda Pharmaceuticals U.S.A., INC. | $60,409.37 | 2023-2025 | Hyqvia, Gammagard |
| Allergan, INC. | $53,149.13 | 2019-2022 | |
| Argenx US, INC. | $4,762.22 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $2,568.45 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,377.32 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $1,106.91 | 2019-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,097.63 | 2019-2025 | |
| Biogen, INC. | $1,057.86 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Eisai INC. | $894.48 | 2019-2025 | |
| Ucb, INC. | $887.66 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Neurocrine Biosciences, INC. | $839.42 | 2022-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $754.75 | 2019-2025 | |
| Amgen INC. | $712.48 | 2019-2025 | Aimovig, Uplizna |
| Mdd US Operations, LLC | $692.39 | 2019-2025 | Gocovri, Gocovri, Myobloc |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $642.02 | 2021-2025 | |
| Lundbeck LLC | $614.67 | 2019-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $586.47 | 2020-2025 | Valtoco |
| Genentech USA, INC. | $463.20 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $459.42 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $387.35 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Amneal Pharmaceuticals LLC | $351.85 | 2019-2025 | Crexont |
| Impel Pharmaceuticals INC. | $326.76 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $325.70 | 2023-2025 | Rexulti, Nuedexta |
| Upsher-Smith Laboratories LLC | $293.86 | 2019-2023 | |
| Tg Therapeutics, INC. | $259.77 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $240.78 | 2022 | |
| Kyowa Kirin, INC. | $234.36 | 2020-2024 | Nourianz |
| Banner Life Sciences, LLC | $222.46 | 2023-2024 | |
| Merz Pharmaceuticals, LLC | $214.37 | 2022-2025 | Xeomin, Inbrija |
| Supernus Pharmaceuticals, INC. | $210.27 | 2019-2025 | Qelbree |
| Adamas Pharmaceuticals, INC. | $201.30 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $190.08 | 2019-2022 | |
| Grifols USA, LLC | $171.05 | 2019-2025 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $167.94 | 2023-2024 | Ztlido |
| Mallinckrodt Hospital Products INC. | $164.63 | 2020-2024 | Acthar |
| Acorda Therapeutics, INC | $133.35 | 2022-2024 | Inbrija |
| Astrazeneca Pharmaceuticals LP | $126.87 | 2024-2025 | Wainua |
| Vanda Pharmaceuticals INC. | $112.49 | 2024-2025 | Ponvory |
| Tanabe Pharma America, INC. | $91.94 | 2021-2025 | Radicava |
| Livanova USA, INC. | $89.15 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Avion Pharmaceuticals | $89.11 | 2021-2023 | Dhivy |
| Janssen Pharmaceuticals, INC | $79.34 | 2022-2024 | Spravato |
| Acadia Pharmaceuticals INC | $74.74 | 2019 | |
| Impel Pharmaceuticals LLC | $70.35 | 2024-2025 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $67.36 | 2021 | |
| Csl Behring | $65.89 | 2025 | Hizentra |
| Ge Healthcare | $62.16 | 2019-2021 | |
| Averitas Pharma INC. | $56.44 | 2023-2025 | Qutenza |
| Boston Scientific Corporation | $52.34 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Catalyst Pharmaceuticals, INC. | $50.35 | 2023-2024 | Fycompa |
| Ani Pharmaceuticals, INC. | $41.71 | 2025 | Purified Cortrophin Gel |
| Assertio Therapeutics, INC. | $41.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.39 | 2020-2021 | |
| Celgene Corporation | $32.22 | 2021-2023 | Zeposia |
| Amylyx Pharmaceuticals, INC. | $31.66 | 2023 | Relyvrio |
| Sanofi-Aventis U.S. LLC | $26.77 | 2020 | |
| Harmony Biosciences LLC | $24.91 | 2025 | |
| Microtransponder, INC. | $24.76 | 2025 | |
| Mallinckrodt Enterprises LLC | $22.45 | 2019 | |
| Bausch Health US, LLC | $22.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.68 | 2025 | |
| Kedrion Biopharma, INC. | $19.18 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Alnylam Pharmaceuticals INC. | $14.09 | 2021 | |
| Currax Pharmaceuticals LLC | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Shaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.